Citation Impact
Citing Papers
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
2014
Targeted therapy of hepatocellular carcinoma: Present and future
2012
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2014 Standout
Hepatocellular carcinoma
2016 Standout
Hepatocellular carcinoma
2018 Standout
Morbidity and Mortality Assessment of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma—A Prospective Study of 70 Consecutive Cases
2006
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
The Thrombospondins
2011 Standout
Hepatocellular carcinoma
2021 Standout
Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies
2009
Sex differences in cancer mechanisms
2020
Lung cancer: current therapies and new targeted treatments
2016 Standout
Virus associated malignancies: The role of viral hepatitis in hepatocellular carcinoma
2014 StandoutNobel
Sex and gender: modifiers of health, disease, and medicine
2020 Standout
Combinations of Bevacizumab With Cancer Immunotherapy
2018
Evaluation of Preoperative Computed Tomography in Estimating Peritoneal Cancer Index in Colorectal Peritoneal Carcinomatosis
2008 Standout
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect
2010 Standout
Genetic Landscape and Biomarkers of Hepatocellular Carcinoma
2015
Hepatocellular Carcinoma
2011
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
2009
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
2021
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Hepatocellular carcinoma
2022 Standout
Targeted Therapies for Hepatocellular Carcinoma
2011
Hepatocellular Carcinoma
2019 Standout
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
2012
Combination therapy in combating cancer
2017 Standout
Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy
2010
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Works of E Popa being referenced
Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma
2008
Effect of CTCAE v4 grading of hypertension on reported toxicity in advanced cancer patients receiving vascular endothelial growth factor (VEGF)-targeting agents.
2013
Sex difference in diffuse malignant peritoneal mesothelioma
2006